Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • FasT CAR-T

    - PMLiVE

    FDA publishes final industry guidance for CAR-T and gene therapies

    The new guidance can also be applied to other genetically modified lymphocyte products, including  CAR NK cells

    - PMLiVE

    Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

    Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

    Avalere Health

    - PMLiVE

    The challenges of reimbursement and innovative pricing for cell and gene therapies

    Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

    Avalere Health

    - PMLiVE

    FDA approves BMS’ blood cancer CAR T therapy after delay

    The FDA's approval of Breyanzi came a year after the start of the review

    - PMLiVE

    BMS/bluebird bio resubmit FDA application for myeloma CAR-T

    Novel CAR-T therapy targets heavily pre-treated myeloma

    - PMLiVE

    Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal

    Closely follows $3bn acquistion of gene therapy specialist Audentes

    Bristol Myers Squibb logo

    Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

    Achieved a 53% complete response rate in study participants

    - PMLiVE

    Launch Excellence 2020

    In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch...

    Blue Latitude Health

    Understanding the evolving CAR-T market

    In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

    Blue Latitude Health

    Precision paediatrics: Treating patients with CAR-T

    Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...

    Blue Latitude Health

    - PMLiVE

    Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

    Expects to file with the FDA next year

    - PMLiVE

    Gracell Bio developing faster, cheaper CAR-T production

    Manufacturing can be cut from two weeks to one day

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links